A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Trial Profile

A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Napabucasin (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms CanStem111P
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2017 According to a Boston Biomedical media release, trial design presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting.
    • 18 May 2017 According to a Boston Biomedical media release, data from this study will be presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top